New treatment of chronic hepatitis B

E.S. Andersen; Nina Weis

New treatment of chronic hepatitis B

E.S. Andersen, Nina Weis

1 Citation (Scopus)

Abstract

Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently
Udgivelsesdato: 2008/11/24

Original language	Danish
Journal	Ugeskrift for læger
Volume	170
Issue number	48
Pages (from-to)	3937-3939
Number of pages	2
ISSN	0041-5782
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{8c7c57708b0511de8bc9000ea68e967b,

title = "New treatment of chronic hepatitis B",

abstract = "Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently Udgivelsesdato: 2008/11/24",

author = "E.S. Andersen and Nina Weis",

year = "2008",

language = "Dansk",

volume = "170",

pages = "3937--3939",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "48",

}

TY - JOUR

T1 - New treatment of chronic hepatitis B

AU - Andersen, E.S.

AU - Weis, Nina

PY - 2008

Y1 - 2008

N2 - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently Udgivelsesdato: 2008/11/24

AB - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently Udgivelsesdato: 2008/11/24

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 170

SP - 3937

EP - 3939

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 48

ER -